Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders
NCT01316796 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28
Last updated 2018-10-22
Summary
Background:
\- Chronic leg ulcers are a complication of many blood disorders such as sickle cell disease, thalassemia, and other red blood cell disorders. In these disorders, red blood cells break down earlier than normal, which researchers suspect may cause or contribute to the development of leg ulcers; however, the exact cause is unknown, and current therapies are not very effective. Researchers are interested in determining if a research cream made with sodium nitrite, a substance that is known to increase blood flow by dilating blood vessels, may speed up the healing of skin ulcers.
Objectives:
\- To evaluate the safety and effectiveness of topical sodium nitrite cream as a treatment for chronic leg ulcers in individuals with sickle cell disease or other red blood cell disorders.
Eligibility:
\- Individuals at least 18 years of age who have sickle cell disease or another red cell disorder and have had a leg ulcer for more than 4 weeks.
Design:
* Participants will be screened with a physical examination, medical history, blood tests, and an examination of the ulcer, including x-ray of the leg(s) with the ulcer and swabs from the wound.
* Participants will be scheduled for a 5-day inpatient stay at the Clinical Center, with the following procedures:
* Days 1 and 2: Participants will have blood draws, a wound assessment, ultrasound of the affected leg, imaging studies (magnetic resonance imaging and infrared photography), thermo-patch application to monitor temperature changes, measurements of blood flow in the skin, and questionnaires about pain and quality of life. An optional skin biopsy may also be conducted with samples taken near the skin ulcer
* Day 3: Participants will have one ulcer treated with the topical cream. Frequent blood draws will be conducted before application and then regularly for up to 6 hours after application of the cream. Thirty minutes after the research cream is applied, participants will have imaging studies of the treated leg and measurements of pain levels and blood flow.
* Day 4: Participants will have a blood draw and temperature recordings taken.
* Day 5: Participants will have the research cream applied and the same imaging studies as before, and will be discharged for care at home.
* For the following 3 weeks, participants will come to the clinical center twice a week to have the research cream applied to the leg ulcer and tests performed by the study researchers.
* For the fourth and final week, participants will return for additional cream treatment sessions, imaging studies, blood draws, and other tests as directed by the study researchers.
* Study participation will end in the following week (week 5). Subjects will come for a final visit one month after the end of the study.
Conditions
- Sickle Cell Anemia
- Sickle Cell Disease
- Chronic Hemolytic Disorders
Interventions
- DRUG
-
Sodium Nitrite Cream
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
lead NIH
Principal Investigators
-
Matthew M Hsieh, M.D. · National Heart, Lung, and Blood Institute (NHLBI)
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-03-15
- Primary Completion
- 2015-09-18
- Completion
- 2018-10-12
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease
NCT06287099 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease
NCT01894594 ·Status: TERMINATED ·Phase: PHASE1
-
Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease
NCT05675436 ·Status: ACTIVE_NOT_RECRUITING
-
Decitabine for High-Risk Sickle Cell Disease
NCT01375608 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Endothelin-1 in Sickle Cell Disease
NCT02712346 ·Status: COMPLETED ·Phase: PHASE1
-
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
NCT00094887 ·Status: COMPLETED ·Phase: PHASE2
-
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
NCT04349189 ·Status: COMPLETED
-
Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function
NCT06145282 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
N-Acetylcysteine in Patients With Sickle Cell Disease
NCT01849016 ·Status: COMPLETED ·Phase: PHASE3
-
Nitric Oxide to Improve Blood Flow in Sickle Cell Disease
NCT00009581 ·Status: COMPLETED ·Phase: PHASE2
-
Microvessels and Heart Problems in Sickle Cell Disease
NCT01602809 ·Status: COMPLETED
-
Screening Patients With Sickle Cell Disease for Kidney Damage
NCT02239016 ·Status: COMPLETED
-
Blood Sampling for Research Related to Sickle Cell Disease
NCT00542230 ·Status: RECRUITING
-
A Study of Oral L-citrulline in Sickle Cell Disease
NCT02659644 ·Status: WITHDRAWN ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
NCT04610866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
NCT04055818 ·Status: RECRUITING ·Phase: PHASE1
-
Carbon Monoxide Levels and Sickle Cell Disease Severity
NCT01547793 ·Status: COMPLETED
-
SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer
NCT02600390 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers
NCT00004412 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Beet Juice for Patients With Sickle Cell Anemia
NCT02162225 ·Status: WITHDRAWN ·Phase: PHASE2
-
Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia
NCT00001197 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease
NCT06287086 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Nitric Oxide and Sickle Cell Pain
NCT01393847 ·Status: TERMINATED
-
Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease
NCT00012545 ·Status: COMPLETED
-
Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease
NCT01568645 ·Status: WITHDRAWN ·Phase: PHASE1